Business Context and Reporting Period
Zevra Therapeutics, Inc. (ZVRA) filed a Form 8-K on August 8, 2024, providing preliminary estimated financial results for the three months ended June 30, 2024. The company is a biopharmaceutical entity focused on the development and commercialization of its product AZSTARYS.
Key Financial Metrics
| Metric | Q2 2024 (Low) | Q2 2024 (High) | Q2 2023 (Restated) |
|---|---|---|---|
| Revenue (in thousands) | $4,200 | $4,600 | $8,470 |
| Net Loss (in thousands) | $(19,800) | $(18,900) | $(2,573) |
| Net Loss Per Share | $(0.47) | $(0.45) | $(0.08) |
| Weighted Avg Shares Outstanding | 41,899,087 | 41,899,087 | 33,898,233 |
Liquidity: As of June 30, 2024, estimated cash and cash equivalents were approximately $49.3 million. The filing does not provide specific data on debt, operating cash flow, or gross margins.
Material Changes vs. Prior Period
- Revenue Decline: Revenue is expected to decrease by between $3.9 million and $4.3 million compared to the prior year period.
- One-Time Milestone Impact: The Q2 2023 revenue included a one-time $5.0 million milestone payment from Commave Therapeutics SA for AZSTARYS reaching $25.0 million in annual net sales. This non-recurring item significantly inflated the prior year comparison.
- Offsetting Factors: The revenue decrease is partially offset by reimbursements under the AZSTARYS License Agreement and expected increases in French expanded access program reimbursements.
- Loss Expansion: Net loss widened significantly from $2.6 million in Q2 2023 to an estimated range of $18.9 million to $19.8 million in Q2 2024.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the preliminary financial information and cash position. Management notes that actual results may differ materially due to risks and uncertainties detailed in the company's Form 10-K and Form 10-Q filings. The financial data presented is preliminary, unaudited, and subject to completion of financial closing procedures; the independent registered public accounting firm has not yet reviewed this information.
Investor Verification Checklist
- Verify the final audited Q2 2024 financial results once the official Form 10-Q is filed to confirm the preliminary estimates.
- Confirm the specific timing and amount of reimbursements from the AZSTARYS License Agreement and French expanded access programs.
- Review the company's cash burn rate and runway given the $49.3 million cash position and significant quarterly losses.
- Assess the impact of the increased share count (from ~33.9M to ~41.9M) on future dilution and per-share metrics.